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ABSTRACT 
Objective: Oral nanoemulsion (NE) represent one of the newest technology to enhance intestinal drug permeability, bioavailability and facilitate 
swallowing of the oral dosage form.  
Methods: In this study, montelukast sodium (MS) nanoemulsions (NEs) were formulated by ultra-sonication using different surfactants (tween 20, 
tween 60 and tween 80) in different surfactant: co-surfactant (ethanol) ratios (Smix). The prepared NEs were evaluated for different parameters 
including droplet size (DS) using zetasizer as a function of ultra-sonication time, dispersibility, phase separation, conductivity, percent 
transmittance, optical transparency, in vitro release in addition to morphology using transmission electron microscopic (TEM).  
Results: The results revealed that F3 was the optimum formula having an average DS 32.95±2.8 nm after 5 min ultra-sonication assured by 
zetasizer and TEM, furthermore, a clear to bluish NE was formed after aqueous dilution with high conductivity (59.2±1.76 μs/cm) which indicated 
the formation of O/W NE. In addition, an optically clear NE was formed with (88.6±2.1) % transmittance with no sedimentation, creaming or 
separation after centrifugation signifying the formation of a stable NE. Finally, F3 showed faster dissolution rate (92.45%±1.66) after 30 min 
compared to other formulas. 
Conclusion: The net result of this study is the formulation of a stable oral NE containing MS which presents new easily swallowed dosage form that 
may enhance drug permeability as well as it may reduce drug metabolism leading to improving bioavailability for asthmatic patients. 
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Although oral administration is the most preferred route for 
administration of pharmaceuticals, it is restricted by swallowing 
difficulty of the solid dosage form in addition to dissolution, 
absorption and bioavailability problems [1, 2].  
For many years, numerous technologies were developed to produce 
easily swallowed dosage forms and to enhance its oral 
bioavailability, from which oral nanoemulsion (NE) was one of the 
most promising investments [3, 4]. 
Nanoemulsions (NEs) are thermodynamically stable dispersion of oil 
and water with deformable droplets in the range of (10–200 nanometre 
“nm”) which have specific physicochemical properties such as low 
viscosity, transparency, optical isotropy and does not have the tendency 
to coalesce due to the presence of a stabilizing surfactant: co-surfactant 
mixture. Their small elastic droplets give them higher stability because 
the diffusion rate is higher than the sedimentation or creaming rate 
induced by the gravity force. NE are classified according to the 
composition of the dispersed phase and dispersion media into three 
types oil in water (O/W), water in oil (W/O) and bicontinuous, were 
each possess certain applications [5-8]. 
Montelukast is a selective leukotriene receptor antagonist used for 
the maintenance treatment of asthma, chronic asthma attacks and to 
relieve symptoms of seasonal allergies. Although montelukast is 
marketed as the sodium salt in the form of tablets and inhalers, no 
liquid dosage form is available because of the stability problem of 
this salt in the aqueous media [9, 10].  
For this reason, this work was adapted to formulate a new oral 
dosage form of montelukast sodium (MS) as nanoemulsion in order 
to produce easily swallowed dosage form that may improve its 
absorption and bioavailability.  
MATERIALS AND METHODS 
Materials 
Tween 20, tween 40, tween 60, tween 80, propylene glycol (PG), 
polyethylene glycol (PEG) 200 and 400 (J. T Baker, China), oleic acid, 
clove oil, lemon oil, cardamom oil, olive oil and orange flavor (CDH, 
India), montelukast sodium (MS) (Sigma Chemical Co. Aldrich, USA), 
deionized distilled water (DDW) was used for all experiments. All 
other reagents, chemicals and solutions used were of analytical grade. 
Construction of phase diagrams 
Pseudo-ternary phase diagrams were constructed by aqueous 
titration method to examine the formation of O/W NE using four 
components: oil (oleic acid), surfactant (tween 80, tween 60, and 
tween 20), co-surfactant (ethanol), and an aqueous phase. The 
diagrams of triangular coordinate were constructed using different 
combination of surfactant/co-surfactant mixtures (Smix) including 
(tween 80: ethanol, tween 60: ethanol and tween 20: ethanol) at the 
desired ratios (1:1, 1:2, 2:1) as listed in the table (1). Emulsion area 
boundaries were programed using different ratios of oil to Smix 
ranging from (1:9 to 9:1). As DDW was added drop by drop to the 
mixture of oleic acid with Smix under gentle stirring. If turbidity 
appeared, followed by phase separation, the samples were 
considered to be biphasic. If clear and transparent mixtures were 
visualized after stirring, the samples were considered monophasic. 
The samples were marked as points in the phase diagram. The area 
covered by these points was considered to be the nanoemulsion 
region of existence [11, 12]. The larger the area of the emulsion in 
the phase diagram was selected as the best NE composition for 
further study because of its better hydration capacity. 
Preparation of montelukast nanoemulsion 
Nanoemulsions were prepared by the ultra-sonication method. The 
composition of the NE was chosen according to the pseudo-ternary 
phase diagram. MS powder (4 mg) was dissolved in the selected oil, 
surfactant and co-surfactant mixture was added in the chosen 
concentration, and flavored DDW (with 1% orange flavor) was 
added dropwise with continuous stirring until clear NE was formed, 
this was followed by utra-sonication to obtain very small droplet 
nanoemulsion. The final concentration of MS in the NE was 4 mg/ml 
as shown in table 1 [13, 14]. 
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Table 1: Composition of montelukast sodium NE 
Formula Surfactant Co-surfactant S./Cos. ratio Oleic acid oil %v/v Smix. %v/v Flavored DDW P* P%v/v Drug mg/ml 
F1 Tween80 Ethanol 1:1 10 60 30 4 
F2 Tween60 Ethanol 1:1 10 60 30 4 
F3 Tween20 Ethanol 1:1 10 60 30 4 
F4 Tween20 Ethanol 1:2 10 60 30 4 
F5 Tween20 Ethanol 2:1 10 60 30 4 
F6 Tween20 Ethanol 1:1 15 60 25 4 
P
*
PAll NE formulas contain 1% orange flavour, P* PAbbreviations: S./Cos. ratio, surfactant/co-surfactant ratio; Smix %, percentage of the surfactant and 
co-surfactant in the NE; DDW, deionized distilled water. 
 
Characterization of montelukast sodium NE 
Saturated solubility study 
The saturated solubility of MS was performed in different oils 
including oleic acid, clove oil, lemon oil, cardamom oil, olive oil in 
addition to the orange flavor. Furthermore, the study also performed 
on different surfactants including tween 20, tween 40, tween 60, 
tween 80, PG, PEG 200 and 400 in addition to different co-surfactants 
including ethanol, isopropanol, and butanol. This was performed by 
shaking an excess amount of MS to 2 ml of each of the previous liquid 
at 25±10 °C for 24 h, finally the supernatant layer was removed 
filtered and analyzed using UV-spectrophotometer at 285 nm [15, 16].  
Droplet size versus ultra-sonication time  
The ultra-sonication time was optimized according to droplet size 
measurement for every formula after different ultra-sonication 
intervals (1, 2, 3, 5 and 10 min). The evaluation of droplet size was 
performed using Nano Zetasizer for each sample, different dilutions 
were performed and the test was done in triplicate to find the mean 
droplet size at 20 °C [17].  
Dispersability test 
Dilution or dispersibility test was performed to assess the physical 
stability of the prepared NEs, since O/W NE is dilutable with water, 
whereas W/O are not and undergo phase inversion into O/W NE. This 
test can be done by taking 1 ml of the prepared NE (F1-F6) and diluted 
it in 500 ml of distilled water with constant stirring at 50 rpm at 37 °C 
and observed for clarity, turbidity or phase separation [18, 19]. 
Phase separation 
NE formulas (F1-F6) were assessed for physical stability by 
centrifugation at 10,000 rpm for a period of 30 min and examined 
for any phase separation [20]. 
Conductance test 
O/w NEs, where the external phase is water, are highly conducting, 
whereas W/O are not, since water is the internal or dispersal phase. 
To determine the nature or type of the continuous phase and to 
detect phase inversion phenomena the electrical conductivity (σ) 
has to be measured and this was done by using a conductometer via 
laying the conductometer probe erect in 10 ml of the prepared 
formula in a beaker at room temperature, and the apparatus will 
register the results in μs/cm [21]. 
Percentage transmittance 
Percentage transmittances (%T) of NE prove the transparency of the 
systems. For measurement of percentage transmittance (%T), NE 
formulas were diluted 10 times with distilled water and %T was 
checked against distilled water using a visible spectrophotometer. 
The percent transmittance of the all formulations was measured at 
285 nm using this equation [22]: 
𝐴𝐴=2−log % 𝑇𝑇 
Where;  
A: absorbance  
%T: transmittance percentage 
Optical transparency 
Optical transparency of the formulas was determined by visually 
inspecting the sample in a clear and transparent container under the 
presence of good light against reflection into the eyes, and viewed 
against black and white illuminated background [23]. 
In vitro drug release studies 
The release of MS from NEs carried out by using dialysis bag MWCO 
(2000 Da). 10 ml MS nanoemulsion containing 40 mg of the drug was 
placed into dialysis bag. USP II rotating paddle apparatus was used to 
measure the in vitro drug release of all formulas. The dissolution 
medium (900 ml of 0.1N HCl) was placed into the release jar maintaining 
the speed of 100 rpm and temperature at 37±0.5 °C. Release studies 
were carried out for 2 h. Five ml of aliquot is withdrawn at an interval of 
5, 10, 20, 30, 45, 60, 90,120 min. After collecting the sample, the 
dissolution medium was replenished with the same volume of fresh 
medium, and the sample was filtered. The samples were analyzed at 285 
nm by UV-visible spectrophotometer [24]. 
Transmission electron microscopic analysis 
Morphology of droplets was observed using transmission electron 
microscopic (TEM). One drop of diluted NE (100 times) was placed 
on a 200-mesh film grid and dried at room temperature; then 
samples were stained using uranyl acetate and allowed to dry for 10 
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Fig. 1: Pseudo-ternary phase diagram of montelukast sodium 
O/W NE formulated using (A) oleic acid, tween20: ethanol 
(Smix 1:1) and DDW, (B) oleic acid, tween: ethanol (Smix 1:2) 
and DDW, (C) oleic acid, tween20: ethanol (Smix 2:1) and DDW 
 
RESULTS AND DISCUSSION 
Construction of phase diagrams 
Fig. 1 clearly signifies the pseudo-ternary phase diagram of MS NE 
constructed using oleic acid and DDW with tween 20 (surfactant) and 
ethanol (co-surfactant) at different Smix ratios. It is obvious that fig. 1(A) 
composed from 1:1 Smix shows the largest stable NE area. Tween 20 is a 
non-ionic surfactant with HLB equals 16.7, having a hydrophilic head 
and ahydrophobic tail, it is used to reduce the interfacial tension (ɣ) 
between oleic acid (oil phase) and water by formation of the protective 
film surrounding the oil droplet, thus reducing contact between oil 
globules and prevent coalescence. On the other hand, ethanol is used as a 
short chain co-surfactant for further reduction of (ɣ) and also to reduce 
viscosity and increase the mobility of hydrophobic tail to enhance more 
penetration on the interphase [26, 27]. 
Evaluation of montelukast nanoemulsion 
Saturated solubility results 
Fig. (2) Clearly demonstrates the solubility of MS in different oil, 
surfactants and co-surfactants. The significantly higher solubility of 
the drug in orange flavor compared to other oils could be explained to 
the higher aqueous solubility of the flavors comparing to the oils [28]. 
On the other hand, the drug possesses higher solubility in tween 
20due to the higher HLB value of (16.7) and hence greater 
hydrophilicity compared to the other grades having lower HLB values 
(15.6, 15, 14.9) for tween40, tween80, tween60 respectively [29]. 
Furthermore, the significantly higher solubility of the drug in the co-
surfactant is arranged in the order PEG 400>PEG 200> 
ethanol>Propanol>isobutanol which might be due the higher 
molecular weight and hydrophilicity of PEG 400 compared to the 
others [30]. 
  
Fig. 2: Saturated solubility of montelukast sodium in different excipients (Results are expressed as mean±SD, n=3) 
 
 
Droplet size and ultra-sonication time evaluation  
Regarding ultra-sonication time, mean droplet size for each formula 
was evaluated and the results are demonstrated in the table (2). The 
data showed a significant reduction in droplet size after increasing 
ultra-sonication time for each formula from 2 to 5 min with the 
disappearance of the droplets after 10 min indicating destruction of 
the internal phase globule after this period. For this reason, ultra-
sonication was fixed at 5 min in the preparation of montelukast NEs 
[31].
 
Table 2: Mean droplet size in nm as a function of ultra-sonication time 
Formula DS/1 min DS/2 min DS/3 min DS/5 min DS/10 min 
F1 204.48±1.3 140.56±3.87 97.73±3.74 64.56±1.4 - 
F2 289.86±3.07 147.32±4.25 86.57±1.04 78.46±1.07 - 
F3 276.66±2.99 99.83±2.98 74.02±4.98 32.95±2.8 - 
F4 347.89±1.98 104.04±1.04 87.64±3.98 48.40±1.03 - 
F5 367±33±5.26 159.02±2.76 98.53±1.04 77.98±3.76 -- 
F6 398.64±2.76 176.05±4.95 102.34±2.8 86.45±4.76 - 
*Abbreviations: DS, mean droplet size; min, minutes. Results are expressed as mean±SD, n=3 
 
Dilution test 
All prepared NEs (F1-F6) gives a clear to clear bluish NE when 
diluted with water. This indicates that all of them are O/W Nano 
emulsion [32]. 
Phase separation 
All prepared NEs were subjected to centrifugation at 3500 rpm for a 
period of 30 min and examined for any change in phase separation. 
The result indicates there is no creaming, sedimentation or phase 
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separation upon centrifugation for all the prepared NE formulas was 
observed, this indicates their stability. This proves that the thermal 
motion of the droplets (Brownian motion) exceeds the external 
forces such as gravitation or centrifugation [33, 34]. 
Conductance test 
Measuring the electrical conductivity using a conductometer for the 
selected formula (F3). The result showed a high conductivity 
(59.2±1.76 μs/cm) proving that formula was O/W because of the 
high conductivity of water. The higher conductivity of NE is 
attributed to a large percentage of water which allows more 
freedom for mobility of ions [35]. 
Percentage transmittance 
The turbidity of the NEs was measured using UV absorbance at 285 
nm. 1The higher absorbance (more turbidity) means lower % 
transmittance. Percentage transmittance of NEs proves the 
translucence of the system. The results of percent transmittance 
indicated that all the prepared formulations were translucent [36], 
as shown in table 3. 
 
Table 3: Percentage transmittance (% T) of prepared nanoemulsion formulations 







*Results are expressed as mean±SD, n=3 
 
Optical transparency  
All the prepared NE formulas were optically clear. Smallest droplet 
size causes weak light scatters (more transparent), and this 
indicated nano-sized emulsion [37]. 
In vitro dissolution study 
Results of in vitro release from montelukast NE were shown in fig. 
(3). The fig. clearly demonstrated a significant increment on drug 
release from F1-F3 formulated using Tween 80, Tween 60 and 
Tween 20 respectively as a surfactant, with a greater degree of 
release represented by F3 from all other formulas (92.45%±1.66 
after 30 min). This can be explained due to the higher HLB value of 
Tween 20 (16.7) comparing to the other surfactants that enhanced 
the solubility and the dissolution of the drug from F3 [38]. 
Furthermore, a high % of drug release with a non-significant 
difference was observed in F4 and F5 formulated by using different 
surfactant: co-surfactant ratios 1:2 and 2:1 could be explained to the 
greater reduction in the surface tension leading to greater hydration 
and smaller droplet size and consequently greater dissolution [39]. 
Transmission electron microscopic (TEM) analysis 
The result of TEM of the optimal formula (F3) demonstrated 
discrete dark globules with bright surroundings with an average 
diameter of 32.95 nm as shown in fig. 4. 
 
 
Fig. 3: In vitro release profile for montelukast NE (F1-F6) in 0.1 N HCl (Results are expressed as mean±SD, n=3) 
 
  
Fig. 4: TEM of optimal montelukast NE formula (F3) 
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The present study indicated the possibility to prepare stable 
nanoemulsion formula containing montelukast sodium with small 
droplet size and high % drug release that can be used orally giving a 
newly easily swallowed dosage form that may improve drug 
absorption through improving drug solubility and dissolution and 
may reduce its hepatic metabolism leading to improving its 
bioavailability that may contribute to reducing its given dose and 
improves patient’s compliance.  
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